Current indications for reduced-intensity allogeneic stem cell transplantation

Best Practice and Research: Clinical Haematology

Volumn 17, Issue 3 SPEC.ISS., 2004, Pages 377-386

  Haddad, Nuhad ^a   Rowe, Jacob M ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

ALL; AML; Myeloma; NHL; Reduced intensity stem cell transplantation

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; BORTEZOMIB; BUSULFAN; CAMPATH 1 H; CANCER VACCINE; CARMUSTINE; CLADRIBINE; CYTARABINE; ETOPOSIDE; FLUDARABINE; IMATINIB; IMMUNOMODULATING AGENT; INTERLEUKIN 2; LENALIDOMIDE; MELPHALAN; THALIDOMIDE; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONSENSUS; CYTOMEGALOVIRUS INFECTION; DONOR; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; EWING SARCOMA; GERM CELL TUMOR; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CARCINOMA; MELANOMA; MULTIPLE MYELOMA; MYELODYSPLASIA; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PUVA; REDUCED INTENSITY CONDITIONING; REDUCED INTENSITY STEM CELL TRANSPLANTATION; REVIEW; SOLID TUMOR; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 7744245806     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2004.06.001     Document Type: Article

References (38)

1. Storb R. Yu C. Wagner J.L. et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation Blood 89 1997 3048-3054
2. Niederwieser D. Maris M. Shizuru J.A. et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases Blood 101 2003 1620-1629
3. Faucher C. Monty M. Vey N. et al. Bone marrow as stem cell source for allogeneic HLA-identical sibling transplantation following reduced-intensity preparative regimen Experimental Hematology 31 2003 873-880
4. Barge R.M. Osanto S. Marijt W.A. et al. Minimal GVHD following in-vitro T cell-depleted allogeneic stem cell transplantation with reduced-intensity conditioning allowing subsequent infusions of donor lymphocytes in patients with hematological malignancies and solid tumors Experimental Hematology 31 2003 865-872
5. Nachbaur D. Kircher B. Eisendle K. et al. Phenotype, function and chimerism of monocyte-derived blood dendritic cells after allogeneic haematopoietic stem cell transplantation British Journal of Haematology 123 2003 119-126
6. Perez-Simon J.A. Kottaridis P.D. Martino R. et al. Nonmyeloablative transplantation with or without alemtuzumab: Comparison between 2 prospective studies in patients with lymphoproliferative disorders Blood 100 2002 3121-3127
7. D'Sa S. Peggs K. Pizzey A. et al. T- and B- cell immune reconstitution and clinical outcome in patients with multiple myeloma receiving T-cell-depleted, reduced-intensity allogeneic stem cell transplantation with an alemtuzumab-containing conditioning regimen followed by escalated donor lymphocyte infusions British Journal of Haematology 123 2003 309-322
8. Morris E.C. Rebello P. Thomson K.J. et al. Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: Relevance for early adoptive immunotherapy and infectious complications Blood 102 2003 404-406
9. Faulkner R.D. Craddock C. Byrne J.L. et al. BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients Blood 103 2004 428-434
10. Nakai K. Mineishi S. Kami M. et al. Antithymocyte globulin affects the occurrence of acute and chronic graft-vs-host disease after a reduced-intensity conditioning regimen by modulating mixed chimerism induction and immune reconstitution Transplantation 75 2003 2135-2143
11. Saito T. Kanda Y. Nakai K. et al. Immune reconstitution following reduced-intensity transplantation with cladribine, busulfan and anti-thymocyte globulin: Serial comparison with conventional myeloablative transplantation Bone Marrow Transplantation 32 2003 601-608
12. McSweeney P.A. Niederwieser D. Shizuru J.A. et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-vs-tumor effects Blood 97 2001 3390-3400
13. Taussig D.C. Davies A.J. Cavenagh J.D. et al. Durable remissions of myelodysplastic syndrome and acute myeloid leukemia after reduced-intensity allografting Journal of Clinical Oncology 21 2003 3060-3065
14. Sayer H.G. Kienast J. Ehninger G. Bornhauser M. Dose-modified, fludarabine-based conditioning for allogeneic hematopoietic stem cell transplantation in 177 patients with acute myeloid leukemia not eligible for conventional transplantation Blood 98 2001 743a
15. Storb R. Mixed allogeneic chimerism and graft-vs-leukemia effects in acute myeloid leukemia Leukemia 16 2002 753-754
16. Storb R. Allogeneic hematopoietic stem cell transplantation-yesterday, today, and tomorrow Experimental Hematology 31 2003 1-10
17. Feinstein L.C. Sandmaier B.M. Hegenbart U. et al. Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission British Journal of Haematology 120 2003 281-288
18. Giralt S. Thall P.F. Khouri I. et al. Melphalan and purine analog-containing preparative regimens: Reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation Blood 97 2001 631-637
19. Das M. Saikia T.K. Advani S.H. et al. Use of a reduced-intensity conditioning regimen for allogeneic transplantation in patients with chronic myeloid leukemia Bone Marrow Transplantation 32 2003 125-129
20. Raiola A.M. Van Lint M.T. Lamparelli T. et al. Reduced intensity thiotepa-cyclophosphamide conditioning for allogeneic haematopoietic stem cell transplants (HSCT) in patients up to 60 years of age British Journal of Haematology 109 2000 716-721
21. Or R. Shapira M.Y. Resnick I. et al. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase Blood 101 2003 441-445
22. Martino R. Giralt S. Caballero M.D. et al. Allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in acute lymphoblastic leukemia: A feasibility study Haematologica 88 2003 555-560
23. Massenkeil G. Nagy M. Lawang M. et al. Reduced intensity conditioning and prophylactic DLI can cure patients with high-risk acute leukaemias if complete donor chimerism can be achieved Bone Marrow Transplantation 31 2003 339-345
24. Robinson S.P. Goldstone A.H. Mackinnon S. et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation Blood 100 2002 4310-4316
25. Khouri I.F. Keating M. Korbling M. et al. Transplant-lite: Induction of graft-vs-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies Journal of Clinical Oncology 16 1998 2817-2824
26. Schetelig J. Thiede C. Bornhauser M. et al. Evidence of a graft-vs-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: The Cooperative German Transplant Study Group Journal of Clinical Oncology 21 2003 2747-2753
27. Dreger P. Brand R. Hansz J. et al. Treatment-related mortality and graft-vs-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning Leukemia 17 2003 841-848
28. Barille-Nion S. Barlogie B. Bataille R. et al. Advances in biology and therapy of multiple myeloma. American Society of Hematology Education Program Hematology 2003 248-278
29. Badros A. Barlogie B. Siegel E. et al. Improved outcome of non-myeloablative allogeneic transplantation in multiple myeloma Journal of Clinical Oncology 20 2002 1295-1303
30. Grosskreutz C. Ross V. Scigliano E. et al. Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation Biology of Blood and Marrow Transplantation 9 2003 453-459
31. Maloney D.G. Molina A.J. Sahebi F. et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma Blood 102 2003 3447-3454
32. Bethge W.A. Hegenbart U. Stuart M.J. et al. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning Blood 103 2004 790-795
33. Childs R. Srinivasan R. Advances in allogeneic stem cell transplantation: directing graft-vs-leukemia at solid tumors Cancer Journal 8 2002 2-11
34. Childs R. Chernoff A. Contentin N. et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation New England Journal of Medicine 343 2000 750-758
35. Bregni M. Dodero A. Peccatori J. et al. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer Blood 99 2002 4234-4236
36. Satoh M. Miyamura K. Yamada M. et al. Haploidentical, non-myeloablative stem-cell transplantation for advanced renal-cell carcinoma Lancet Oncology 5 2004 125-126
37. Childs R. Bradstock K. Gottlieb D. et al. Non-myeloablative allogeneic stem cell transplantation (NST) for metastatic melanoma: Nondurable chemotherapy responses without clinically meaningful graft-vs-tumor (GVT) effects Blood 100 2002 1661a
38. Blaise D. Bay J.O. Faucher C. et al. Reduced intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors Blood 103 2004 435-441